Patient's question:
Diagnosed with diffuse large B-cell lymphoma in 2014, completed chemotherapy in June 2015.Doctor's answer:
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for almost one-third of all cases. This type of lymphoma represents the majority of cases previously classified as "aggressive" or "intermediate to high-grade" lymphomas. The correct diagnosis of DLBCL requires expertise from a hematopathology specialist based on evidence from appropriate biopsies and B-cell immunophenotyping. Recent data from multiple international, multicenter, randomized controlled clinical trials have demonstrated that the standard first-line treatment regimen should be rituximab (R) CHOP, and that better efficacy can be achieved by increasing the dose density of the regimen and shortening the interval between cycles, such as the R-CHOP14 regimen.